Bessemer Group
KRYS icon

Bessemer Group’s Krystal Biotech KRYS Stock Holding History

Bessemer Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.54M Hold
20,285
– – 0.01% 458
2026
Q1 		$5.24M Buy
20,285
+25
+0.1% +$6.65K 0.01% 471
2025
Q4 		$5M Buy
20,260
+20,111
+13,497% +$4.23M 0.01% 419
2025
Q3 		$26K Buy
149
+77
+107% +$11.5K ﹤0.01% 1619
2025
Q2 		$10K Buy
72
+3
+4% +$441 ﹤0.01% 1821
2025
Q1 		$12K Buy
69
+15
+28% +$2.52K ﹤0.01% 1706
2024
Q4 		$8K Sell
54
-18
-25% -$3.19K ﹤0.01% 1860
2024
Q3 		$13K Buy
72
+32
+80% +$6.17K ﹤0.01% 1600
2024
Q2 		$7K Buy
+40
New +$6.72K ﹤0.01% 1614
2020
Q3 		– Sell
-29,500
Closed -$1.22M – 1518
2020
Q2 		$1.22M Buy
29,500
+17,500
+146% +$842K ﹤0.01% 667
2020
Q1 		$519K Buy
+12,000
New +$628K ﹤0.01% 767

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bessemer Group's KRYS Position: Q2 2026 in Review

Bessemer Group held its Krystal Biotech (KRYS) position steady in Q2 2026 at 20,285 shares worth $7.54M. The position accounts for 0.01% of the portfolio, ranked #458.

Bessemer Group first reported a position in KRYS in Q1 2020 and has held it in 11 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Bessemer Group held 20,285 shares of Krystal Biotech worth $7.54M as of Q2 2026.
  • Bessemer Group left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up 0.01% of Bessemer Group's portfolio in Q2 2026, its #458 holding.
  • Bessemer Group first reported a position in Krystal Biotech in Q1 2020 and has held it in 11 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.